An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Exscientia (Nasdaq: EXAI) announced that Andrew Hopkins, CEO, and Dave Hallett, COO, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 9:20 a.m. PT. A live webcast will be accessible on the company's website, with an archived replay available for 30 days post-presentation. Exscientia is an AI-driven pharmatech company focused on revolutionizing drug discovery and development, with over 30 projects actively in progress, aiming to enhance patient outcomes through advanced treatment options.
Positive
None.
Negative
None.
OXFORD, England--(BUSINESS WIRE)--
Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, and Dave Hallett, Chief Operations Officer, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 9:20 a.m. P.T. (5:20 p.m. BST).
A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
